Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

559 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Rationale and design of the Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart Failure Trial (ARISE-HF) in patients with high-risk diabetic cardiomyopathy.
Januzzi JL Jr, Butler J, Del Prato S, Ezekowitz JA, Ibrahim NE, Lam CSP, Lewis GD, Marwick TH, Rosenstock J, Tang WHW, Zannad F, Lawson F, Perfetti R, Urbinati A. Januzzi JL Jr, et al. Among authors: del prato s. Am Heart J. 2023 Feb;256:25-36. doi: 10.1016/j.ahj.2022.11.003. Epub 2022 Nov 11. Am Heart J. 2023. PMID: 36372245 Free article. Clinical Trial.
Practical algorithms for early diagnosis of heart failure and heart stress using NT-proBNP: A clinical consensus statement from the Heart Failure Association of the ESC.
Bayes-Genis A, Docherty KF, Petrie MC, Januzzi JL, Mueller C, Anderson L, Bozkurt B, Butler J, Chioncel O, Cleland JGF, Christodorescu R, Del Prato S, Gustafsson F, Lam CSP, Moura B, Pop-Busui R, Seferovic P, Volterrani M, Vaduganathan M, Metra M, Rosano G. Bayes-Genis A, et al. Among authors: del prato s. Eur J Heart Fail. 2023 Nov;25(11):1891-1898. doi: 10.1002/ejhf.3036. Epub 2023 Sep 26. Eur J Heart Fail. 2023. PMID: 37712339 Free article.
The growing clinical effect of SGLT2 inhibitors.
Del Prato S. Del Prato S. Lancet Diabetes Endocrinol. 2023 Apr;11(4):218-219. doi: 10.1016/S2213-8587(23)00065-7. Epub 2023 Mar 3. Lancet Diabetes Endocrinol. 2023. PMID: 36878241 No abstract available.
Impact of baseline FIB-4 score on efpeglenatide benefits on cardiovascular outcomes in people with type 2 diabetes: a participant-level exploratory analysis of the AMPLITUDE-O trial.
Del Prato S, Li Z, Ramasundarahettige C, Branch KRH, Lam CSP, Lopes RD, Pratley R, Rosenstock J, Sattar N, Gerstein HC. Del Prato S, et al. Cardiovasc Diabetol. 2024 Sep 28;23(1):352. doi: 10.1186/s12933-024-02432-7. Cardiovasc Diabetol. 2024. PMID: 39342203 Free PMC article. Clinical Trial.
Comparative renal outcomes of matched cohorts of patients with type 2 diabetes receiving SGLT2 inhibitors or GLP-1 receptor agonists under routine care.
Fadini GP, Longato E, Morieri ML, Bonora E, Consoli A, Fattor B, Rigato M, Turchi F, Del Prato S, Avogaro A, Solini A; DARWIN-Renal Study Investigators. Fadini GP, et al. Among authors: del prato s. Diabetologia. 2024 Nov;67(11):2585-2597. doi: 10.1007/s00125-024-06251-z. Epub 2024 Aug 23. Diabetologia. 2024. PMID: 39177691 Free PMC article.
559 results